Controversies and Recent Advances in Hematopoietic Cell Transplantation for Follicular Non-Hodgkin Lymphoma

Table 1

Randomized prospective trials addressing the role of autologous transplantation in follicular lymphoma patients in first remission.

Study group; (year)	Number of patients	TRM in HDT versus C	EFS/PFS in HDT versus C (years)	OS in HDT versus C (years)	Comments
GLSG (2004)	307	<2.5% in both arms	64% versus 33%; P < 0.0001 [5]	Not reported	Significantly more sMDS/AML with HDT (3.5% versus 0%; P = 0.02)
GELA (2006)	402	Not reported	38% versus 28%; P = 0.11 [7]	76% versus 71%; P = 0.53 [7]	Secondary malignancy similar in both groups—14 with chemotherapy and 11 with HDT
GOELAMS (2009)	166	Not reported	64% versus 39%; P = 0.004 [9]	76% versus 80%; P = 0.55 [9]	Significantly more secondary malignancies with HDT (𝑛=12 versus 1; 𝑃=0.01)
GITMO (2008)	136	𝑛=3 versus 𝑛=2 at 100 days	61% versus 28%; P < 0.01 [4]	81% versus 80%; P = 0.96 [4]	4-year MDS/AML was higher with HDT (6.6% versus 1.7%)

Abbreviations: GLSG: german low grade lymphoma study group; GELA: groupe d’etude des lymphomes de l’adulte; GOELAMS: groupe ouest-est des leucémies et autres maladies du sang; GITMO: gruppo italiano trapianto di midollo osseo; TRM: treatment-related mortality; HDT: high-dose therapy and autologous HCT arm; C: chemotherapy arm; EFS/PFS: event/progression-free survival; OS: overall survival; sMDS: secondary myelodysplastic syndrome; AML: acute myeloid leukemia.